# Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

> **NCT00770081** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 75 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Renal Insufficiency

## Interventions

- **DRUG:** vildagliptin
- **DRUG:** sitagliptin

## Key facts

- **NCT ID:** NCT00770081
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770081, "Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00770081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*